welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Solid Biosciences Reports First Quarter 2019 Financial Results and Provides Business Update
Solid Biosciences Inc. (Nasdaq: SLDB) today reported financial results for the first quarter ended March 31, 2019 and provided a business update.
“We have continued to advance our programs for Duchenne muscular dystrophy over the last few months, particularly our lead microdystrophin gene therapy candidate, SGT-001. Building on our findings from the preliminary Phase I/II clinical data that we announced in February, we initiated dosing at 2E14 vg/kg in the second cohort of patients,” said Ilan Ganot, Chief Executive Officer, President and Co-Founder of Solid Biosciences. “Now, we are working to progress as quickly as possible, and we look forward to providing additional data later this year.”
rareRelated
-
Bespoke Is Often Better: How Scientists Are Customizing Gene TherapyWhen it comes to products from suits to ...
-
Gene editing emerges as a new therapeutic strategy for Duchenne muscular dystrophyAdvances in gene editing technology have...
-
Upgrading the toolbox for Duchenne muscular dystrophy research with a new rabbit modelResearch to improve our understanding of...
-
From Flask to Vat: The Challenges of Scaling Up Gene TherapyOver the past two decades, gene therapy ...
-
Making Gene Editing a Therapeutic RealityThis review discusses current bottleneck...
-
A Study to Evaluate the Safety and Tolerability of PF-06939926 Gene Therapy in Duchenne Muscular DystrophyThis is a first-in-human/first-in-patien...
-
Gene Therapy for Duchenne Muscular DystrophyGene Therapy for Duchenne Muscular Dyst...
